Literature DB >> 33415156

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia.

Susi Susanah1, Ponpon S Idjradinata1, Nur M Sari1, Lulu E Rakhmilla2, Yunia Sribudiani3, Jessica O Trisaputra4, Octawyana Moestopo4.   

Abstract

BACKGROUND: Iron overload is still a major complication of severe β-thalassemia. Indication to start iron chelation therapy is based on serum ferritin (SF) or transferrin saturation (TS) level or the amount of transfusion. The goal of this study is to analyse the pattern of iron status, the amount of transfusion regarding the time to start iron chelator, and serum hepcidin levels in newly diagnosed severe β-thalassemia.
METHODS: A prospective cohort study was performed at Hasan Sadikin General Hospital on newly diagnosed severe β-thalassemia patients. Subjects had not received any blood transfusion with normal liver function test, CRP, and IL-6 levels who consumed normal diet according to age. The SF and TS levels indicate iron status, while hepcidin level indicates iron regulator status. Main indicator to start iron chelation therapy when SF level ≥1.000 ng/mL, TS level ≥70%, or after receiving transfusion at least 10 times. Statistical analysis used Mann-Whitney and Spearman.
RESULTS: Forty-two newly severe β-thalassemia, 30 (71.4%), were diagnosed before 1 year old, mean 9.9 ± 6.4 months, range 2-24 months. Range amount of transfusion until SF level reached ≥1,000 ng/mL were 4-12 times, mean 7 ± 2 times. Mean SF and TS level at diagnosis were 365.6 ± 194.9 ng/mL and 67.3 ± 22.5%, while hepcidin level was normal, mean 242.6 ± 58 ng/mL. 36/42 patients have reached SF >1000 ng/mL with amount of transfusion less than 10 times. There was no significant difference of SF, TS, and hepcidin levels when SF >1000 ng/mL in the group with amount of transfusion 7-12 and less than 7 (p = 0.454, p = 0.084, p = 0.765), respectively. A significant positive correlation between SF and amount of transfusion was observed (p < 0.001; r = 0.781).
CONCLUSION: Iron overload in severe β-thalassemia patients might occur earlier even before they received 10 times transfusion. Hepcidin serum level tends to increase when iron overload just started.
Copyright © 2020 Susi Susanah et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33415156      PMCID: PMC7752293          DOI: 10.1155/2020/8185016

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  24 in total

Review 1.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

2.  Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.

Authors:  John B Porter; Mohsen El-Alfy; Vip Viprakasit; Stephane Giraudier; Lee Lee Chan; Yongrong Lai; Ali El-Ali; Jackie Han; Maria D Cappellini
Journal:  Eur J Haematol       Date:  2015-06-23       Impact factor: 2.997

3.  Clinicoinvestigational and demographic profile of children with thalassemia major.

Authors:  Amita Trehan; Nivedita Sharma; Reena Das; Deepak Bansal; R K Marwaha
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-20       Impact factor: 0.900

Review 4.  Hepcidin and Hfe in iron overload in beta-thalassemia.

Authors:  Sara Gardenghi; Pedro Ramos; Antonia Follenzi; Niva Rao; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

5.  Hepcidin in beta-thalassemia.

Authors:  Elizabeta Nemeth
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

Review 6.  Beta-thalassemia.

Authors:  Renzo Galanello; Raffaella Origa
Journal:  Orphanet J Rare Dis       Date:  2010-05-21       Impact factor: 4.123

Review 7.  Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?

Authors:  Thomas D Coates; Susan Carson; John C Wood; Vasilios Berdoukas
Journal:  Ann N Y Acad Sci       Date:  2016-03       Impact factor: 5.691

8.  Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.

Authors:  Ariel Koren; Daniel Fink; Osnat Admoni; Yardena Tennenbaum-Rakover; Carina Levin
Journal:  Eur J Haematol       Date:  2010-01-01       Impact factor: 2.997

9.  Study of serum hepcidin in hereditary hemolytic anemias.

Authors:  Amal El Beshlawy; Ibrahim Alaraby; Mohamed S E M Abdel Kader; Dina H Ahmed; Hossam E M Abdelrahman
Journal:  Hemoglobin       Date:  2012-10-23       Impact factor: 0.849

10.  Effect of breastfeeding versus infant formula on iron status of infants with beta thalassemia major.

Authors:  Usama Roshdy El Safy; Manar Mohamed Fathy; Tamer Hasan Hassan; Marwa Zakaria; Mohamed Abdel Kader Al Malky; Mohamed Arafa; Hany El Sayed; Ashgan Al Ghobashy; Boshra Zaho; Attia Abdel Wahab; Mohamed Hosam Mourad
Journal:  Int Breastfeed J       Date:  2017-04-17       Impact factor: 3.461

View more
  1 in total

1.  Evaluation of thyroid hormones and ferritin level in patients with β-thalassemia.

Authors:  Sura Zahim Hussein
Journal:  Med Pharm Rep       Date:  2022-04-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.